Collegium Pharmaceutical (COLL) reported $145.28 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 7.2%. EPS of $1.62 for the same period compares to $1.26 a year ago. The reported revenue represents a surprise of +1.08% over the Zacks Consensus Estimate of $143.73 million. With the consensus EPS estimate being $1.56, the EPS surprise was +3.85%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compar ...